368 related articles for article (PubMed ID: 10809213)
1. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
[TBL] [Abstract][Full Text] [Related]
2. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
DeNardo GL; Kukis DL; Shen S; DeNardo DA; Meares CF; DeNardo SJ
Clin Cancer Res; 1999 Mar; 5(3):533-41. PubMed ID: 10100704
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
4. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
DeNardo SJ; DeNardo GL; Kukis DL; Shen S; Kroger LA; DeNardo DA; Goldstein DS; Mirick GR; Salako Q; Mausner LF; Srivastava SC; Meares CF
J Nucl Med; 1999 Feb; 40(2):302-10. PubMed ID: 10025839
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
O'Donnell RT; Shen S; Denardo SJ; Wun T; Kukis DL; Goldstein DS; Denardo GL
Anticancer Res; 2000; 20(5C):3647-55. PubMed ID: 11268433
[TBL] [Abstract][Full Text] [Related]
6. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Mirick GR; DeNardo SJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
[TBL] [Abstract][Full Text] [Related]
7. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Carr CE; Mirick GR; DeNardo SJ
J Nucl Med; 1999 Dec; 40(12):2014-20. PubMed ID: 10616879
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
10. Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.
DeNardo GL; DeNardo SJ; Kukis DL; O'Donnell RT; Shen S; Mirick GR; Meares CF
J Nucl Med; 2001 Sep; 42(9):1324-33. PubMed ID: 11535720
[TBL] [Abstract][Full Text] [Related]
11. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
[TBL] [Abstract][Full Text] [Related]
12. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
[TBL] [Abstract][Full Text] [Related]
13. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
[TBL] [Abstract][Full Text] [Related]
14. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
Richman CM; DeNardo SJ; O'Donnell RT; Goldstein DS; Shen S; Kukis DL; Kroger LA; Yuan A; Boniface GR; Griffith IJ; DeNardo GL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
[TBL] [Abstract][Full Text] [Related]
16. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
O'Donnell RT; Leigh BR; Christensen SD; Goldstein DS; Kukis DL; Shen S; Yuan A; DeNardo DA; Kroger LA; DeNardo GL
Cancer Biother Radiopharm; 1999 Jun; 14(3):167-76. PubMed ID: 10850301
[TBL] [Abstract][Full Text] [Related]
18. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
[TBL] [Abstract][Full Text] [Related]
19. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
